It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Zinc (Zn2+) can modulate platelet and coagulation activation pathways, including fibrin formation. Here, we studied the (patho)physiological consequences of abnormal platelet Zn2+ storage and release. To visualize Zn2+ storage in human and mouse platelets, the Zn2+ specific fluorescent dye FluoZin3 was used. In resting platelets, the dye transiently accumulated into distinct cytosolic puncta, which were lost upon platelet activation. Platelets isolated from Unc13d−/− mice, characterized by combined defects of α/δ granular release, showed a markedly impaired Zn2+ release upon activation. Platelets from Nbeal2−/− mice mimicking Gray platelet syndrome (GPS), characterized by primarily loss of the α-granule content, had strongly reduced Zn2+ levels, which was also confirmed in primary megakaryocytes. In human platelets isolated from patients with GPS, Hermansky-Pudlak Syndrome (HPS) and Storage Pool Disease (SPD) altered Zn2+ homeostasis was detected. In turbidity and flow based assays, platelet-dependent fibrin formation was impaired in both Nbeal2−/− and Unc13d−/− mice, and the impairment could be partially restored by extracellular Zn2+. Altogether, we conclude that the release of ionic Zn2+ store from secretory granules upon platelet activation contributes to the procoagulant role of Zn2+ in platelet-dependent fibrin formation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 University Hospital and Rudolf Virchow Center, University of Würzburg, Institute of Experimental Biomedicine, Würzburg, Germany (GRID:grid.8379.5) (ISNI:0000 0001 1958 8658)
2 Maastricht University, Department of Biochemistry, CARIM, Maastricht, The Netherlands (GRID:grid.5012.6) (ISNI:0000 0001 0481 6099)
3 Practice for Pediatric Hematology and Hemostaseology, Munich, Germany (GRID:grid.8379.5)
4 University Hospital Würzburg, Medical Clinic and Policlinic II, Division of Hepatology, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
5 Practice for Pediatric Hematology and Hemostaseology, Munich, Germany (GRID:grid.411760.5)
6 Haemostasikum, Munich, Germany (GRID:grid.411760.5)
7 Institut Hospitalo-Universitaire LIRYC, Plateforme Technologique d’Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac, France (GRID:grid.414477.5) (ISNI:0000 0004 1798 8115)
8 University Medicine Greifswald, Institute for Immunology and Transfusion Medicine, Greifswald, Germany (GRID:grid.5603.0)
9 Justus Liebig University, Institute for Clinical Immunology and Transfusion Medicine, Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627)